UC researchers have found a potential new combination therapy for breast cancer that would integrate use of the body's immune system with targeted treatment for a particular protein that advances cancer.

The study, published in the journal Cancer Research, a journal of the American Association for Cancer Research, provides data that could eventually lead to a new breast cancer therapy, says co-lead author Syn Kok Yeo, Ph.D., research instructor in the department of cancer biology and a member in the lab of Jun-Lin Guan, the Francis Brunning Professor and Cancer Biology Department Chair.

"Cancer immunotherapy uses a patient's immune system against tumor cells," Yeo says. "It has emerged as a crucial treatment strategy, resulting in stable outcomes for cancer patients. However, most breast cancers are not responsive to immunotherapy, and this remains a colossal hurdle."

In this study, researchers found that targeting a protein called FIP200 could "overwrite" the nonresponsive nature of breast cancers to certain immunotherapies, called immune checkpoint inhibitors.

"Disruption of the protein's functions in tumor cells could essentially turn 'cold', or nonresponsive, tumors into 'hot', or responsive, tumors, susceptible to immunotherapy," Yeo says. "Tumors that didn't have this protein contained more T-cells, which is indicative of an immunologically 'hot' tumor. When coupled with immune checkpoint inhibitors in animal models with breast cancer, improved outcomes were observed when the protein wasn't present.

"These findings indicate that targeting FIP200 could create a 'hot spot' for immunotherapy within these tumors."

These findings expand upon previous studies by Guan's lab that identified a tumor-promoting role of the protein in breast cancer.

"While the function of this protein in a cell-recycling process was previously identified as a culprit in breast cancer growth and progression, targeting this function did not make the tumors susceptible to immunotherapy," Yeo adds. "This would imply that the protein has many roles in the development of breast cancer and targeting all of them simultaneously could improve treatment outcomes.

"Future studies are needed to develop therapeutic agents against this protein, to be used in combination with immunotherapy. These findings form a foundation for future clinical trials involving drugs that target the protein in breast cancers.

ISSN: 2155-9899
Journal Impact Factor: 2.3*
NLM title abbreviation: J Clin Cell Immunol
NLM ID: 101563152
ICV: 82.55
DOI: 10.35248/2155-9899
Publication policy: Open Access
Contact email: immunology@eclinicalsci.com

JCCI is a prestigious peer-reviewed, open access journal publishing articles in the field of Immunology since 2010.

We are accepting the following types of manuscript: Research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

All submitted material is subjected to a strict peer-review process. All correspondence, including notification of the Editor's decision (or) review comments and requests for revision, takes place by e-mail.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Authors can submit manuscripts online at Editorial Tracking System (https://www.longdom.org/submissions/clinical-cellular-immunology.html) or forwarded to the Editorial Office at: immunology@eclinicalsci.com

Benefits of Publication with us:

• Fast track Peer-review process in 21 days.
• Publication immediately after acceptance.
• Peer-review by international experts.
• Enhanced visibility for the published articles through digital media & Open-Access.

Media Contact:
Mercy Eleanor | Managing Editor
Journal of Clinical & Cellular Immunology
Whatsapp No:  +1-504-608-2390
Email: immunology@eclinicalsci.com